Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Articles|August 18, 2021
Pharmacy Clinical Pearl of the Day: Non-alcoholic Steatohepatitis
Author(s)Saro Arakelians, PharmD
Non-alcoholic steatohepatitis is the most severe form of non-alcoholic fatty liver disease.
Advertisement
Clinical Pearl of the Day: Non-alcoholic steatohepatitis (NASH)
NASH is defined as the liver manifestation of a metabolic disorder and is the most severe form of non-alcoholic fatty liver disease (NAFLD).
Explanation:
- NAFLD is a condition in which fat builds up in the liver.
- Nonalcoholic fatty liver (NAFL) and NASH are types of NAFLD.
- Patients with NASH, develop inflammation and liver damage, along with fat in the liver.
- Physicians use patients’ medical history, a physical exam, and tests to diagnose NAFLD.
- They can also use blood tests, imaging tests, and liver biopsy to diagnose NAFLD and tell the difference between NAFL or NASH.
Reference
Advertisement
Related to this article
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5